Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose liposomal bupivacaine brachial plexus block for postoperative pain after arthroscopic rotator cuff repair
ChiCTR2600127518Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in rotator cuff tear and Rotator cuff deficiency (RCD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: NRS AUC for postoperative resting pain over 48 hours. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
rotator cuff tearRotator cuff deficiency (RCD)
Beyond the preview
Go deeper on ChiCTR2600127518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127518.